|Transaction:||Public Defence and Takeovers|
|Deal value:||Not disclosed|
|Industry:||Healthcare & Medtech|
ALK is the world leader in allergy vaccination (immunotherapy). Headquartered in Hørsholm, Denmark, ALK has approximately 1,700 employees with subsidiaries, production facilities and distributors worldwide.
Artu Biologiclas is the leading provider of oral allergy vaccination products in the Netherlands. Artu Biologicals parents company Fornix Biosciences is listed on Euronext.
The acquisition of Artu is part of ALK's strategy of expanding its global presence and of contributing to the consolidation of the allergy vaccine industry caused by increased regulatory requirements to products. The acquisition will strengthen ALK's market position in the Netherlands and give it a stronger platform for continued growth in its sales of GRAZAX® and other products. Moreover, ALK will use its new market position to distribute coming tablet-based vaccines. Artu's leading position in the Dutch market is based on close collaboration with allergy doctors within diagnostics and treatment.